Unlike current treatments on the market for hereditary angioedema, navenibart requires dosing only every 3-6 months.

Angioedema is the swelling under the skin caused by allergies, infections, or genetics. Angioedema can cause breathing ...

Deucrictibant significantly improved the time to onset of symptom relief, defined as PGI-C of at least “a little better”, compared with placebo (1.28 vs >12 hours). Topline data were announced from a ...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom ...

For many decades since its initial characterization by Sir William Osler in 1888, hereditary angioedema (HAE) attacks could only be managed symptomatically and there was no way to prevent occurrence ...

BioCryst Pharmaceuticals, Inc. announced promising new data regarding their oral prophylactic treatment, ORLADEYO (berotralstat), for hereditary angioedema (HAE) during the 14th C1-Inhibitor ...

Hereditary angioedema (HAE) is a genetic condition that causes bouts of swelling in the tissue under your skin. The uncomfortable swelling can happen in many different parts of your body, including ...

Pharvaris has announced promising data regarding deucrictibant, a novel oral bradykinin B2 receptor antagonist, presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop. Deucrictibant ...

The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...